Autologous Bone Marrow Mesenchymal Stem Cell Therapy in the Subacute Stage of Traumatic Brain Injury by Lumbar Puncture

Abstract

Objectives: To explore the clinical therapeutic effects and safety of autologous bone marrow mesenchymal stem cell therapy for traumatic brain injury by lumbar puncture. Materials and Methods: A total of 97 patients (24 with persistent vegetative state and 73 with disturbance motor activity) who developed a complex cerebral lesion after traumatic brain injury received autologous bone marrow mesenchymal stem cell therapy voluntarily. The stem cells were isolated from the bone marrow of the patients and transplanted into the subarachnoid space by lumbar puncture. Results: Fourteen days after cell therapy, no serious complications or adverse events were reported. To a certain extent, 38 of 97 patients (39.2%) improved in the function of brain after transplant (P = .007). Eleven of 24 patients (45.8%) with persistent vegetative state showed posttherapeutic improvements in consciousness (P = .024). Twentyseven of 73 patients (37.0%) with a motor disorder began to show improvements in motor functions (P = .025). The age of patients and the time elapsed between injury and therapy had effects on the outcomes of the cellular therapy (P < .05). No correlation was found between the number of cell injections and improvements (P > .05). Conclusions:This study suggests that the bone marrow stem cell therapy is safe and effective on patients with traumatic brain injury complications, such as persistent vegetative state and motor disorder, through lumbar puncture. Young patients improve more easily than older ones. The earlier the cellular therapy begins in the subacute stage of traumatic brain injury, the better the results.

Adult stem cells in neural repair: Current options, limitations and perspectives

“…We must also understand these cells' mechanisms of interaction and how we can use these mechanisms to achieve full regeneration. Based on the studies cited here, it is possible to affirm that in the near future we will have effective therapies against various diseases that affect and challenge the medical community and the population [53] 2013 20 22-54 yr MSCs -6 mo García-Santos et al [54] 2013 11 33-61 yr MSCs -12 mo Tian et al [55] [20] 2012 31 10-50 yr BMCs -33 mo Martínez et al [57] 2012 67 49.2 ± 10.3 1 yr CD133+ -12 mo Mazzini et al [28] 2012 19 20-75 yr MSCs -108 mo Moviglia et al [47] 2012 7 33-78 yr NSCs T-cell vaccine 12 mo Prasad et al [58] 2012 11 30-70 yr MNCs -52 wk Brazzini et al [59] 2010 53 38-81 yr BMCs -1-18 mo Karussis et al [26] 2010 19 53.0 1 yr MSCs -25 mo Lee et al [60] 2010 16 64.0 ± 11.6 1 yr MSCs -5 yr Venkataramana et al [61] …”

Acute promyelocytic leukemia following autologous bone marrow-derived mesenchymal stem cell transplantation for traumatic brain injury: A case report

“…Studies have shown that neurons differentiated from MSCs exhibit functional (9). Compared with the other cell types, autologous BMMSCs avoid ethical controversy and immune rejection, and can be easily obtained through repeated harvests (7). Hence, BMMSCs has become an important source of seed cells for the treatment of a wide variety of nervous diseases.…”

“…TBI always destroy neurons, glial cells, nerve fibers and blood vessels directly, and the effective treatment of neurological impairment has been a widespread problem in clinical practice (7). Early studies suggested that the CNS had no ability to renew or regenerate after injury.…”

“…Human bone marrow MSCs (BMMSCs) have been widely studied, as they are relatively easy to access and they have potential to differentiate into the osteogenic, adipogenic and chondrogenic lineages, and into hepatocytes, cardiomyocytes, neurons and other types of tissues or cells (6). Previous studies have reported that transplanted BMMSCs accelerated neuroplasticity and facilitated neuronal regeneration, as well as functional recovery (7). Currently, autologous BM-derived stem cell transplantation s is one of the most common procedures in stem cell research.…”

Traumatic Brain Injury: Current Treatment Strategies and Future Endeavors

“…[96][97][98][99] Several clinical trials in cell-based treatment for TBI recovery have demonstrated safety of this therapeutic approach. 100,101 However, the administration route, dose, and time window still remain controversial.…”